Skip to content

Database for Clinical and Anamnestic Data in Pulmonary Hypertension

Database for Clinical and Anamnestic Data in Pulmonary Hypertension

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01607502
Enrollment
900
Registered
2012-05-30
Start date
2010-07-31
Completion date
2027-07-31
Last updated
2026-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Hypertension

Keywords

Pulmonary hypertension, database, biomarker

Brief summary

Pulmonary hypertension (PH) is defined as a pulmonary arterial mean pressure (meanPAP) ≥ 25 mmHg measured in the right heart catheterization. There are different forms of PH defined in the classification of Dana Point 2008. PH is diagnosed with right heart catheterization but there are other non invasive methods which can be used for screening like the echocardiography, stress echocardiography and cardio pulmonary exercise testing. In the diagnosis process and in the follow up of PH patients biomarkers like NTproBNP are helpful. There are no specific biomarkers for the disease which can make the diagnosis process easier and predict prognosis. The systematic data collection in a data base provides better information about patients in daily routine and clinical studies as well as in the design of new studies.

Detailed description

In this study the investigators want to collect clinical data of PH patients and controls in a database as well as blood samples in a biobank. The combination of anamnestic and clinical data and biomarkers should provide a better characterization of our patients and should improve the analysis of the disease development of different PH forms and therapeutic aspects. After given informed consent patients' data are entered in a database at different time points. The database includes parameter of several invasive and non-invasive investigations like right heart catheterization (RHC), echocardiography, ECG, pulmonary function tests, cardiorespiratory exercise testing, 6-minute walk test, computed tomography, MRI, polysomnography, blood gas analysis and laboratory data as well as demographic data of the patients. The blood samples are taken during routine punctuation and are stored in our biobank.

Interventions

None listed

Sponsors

Medical University of Graz
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients with pulmonary hypertension * patients at risk for getting pulmonary hypertension * patients who have symptoms which my be due to pulmonary hypertension when we have their written informed consent.

Exclusion criteria

* patients without written informed consent

Design outcomes

Primary

MeasureTime frameDescription
Collecting data in a PH patient databaseAfter one year: first analysis of retrospectively collected data. Ongoing data collection: new data of patients who are already in the database, new patients (3-4 years)Retrospective and prospective data input and constant update

Countries

Austria

Contacts

Primary ContactHorst Olschewski, MD
horst.olschewski@medunigraz.at+43-316-385-12183
Backup ContactMaria Tscherner, MD
m.tscherner@medunigraz.at+43-316-385-12183

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 28, 2026